The United States has begun a new phase of its COVID-19 vaccination campaign with updated mRNA booster shots designed to target both the original SARS-CoV-2 strain and the Omicron BA.4 and BA.5 subvariants now dominating transmission. The change is the first reformulation of the widely used Pfizer-BioNTech and Moderna vaccines since the products were introduced and effectively replaces prior monovalent booster recommendations for the age groups covered.

CDC Director Rochelle Walensky on September 1 endorsed recommendations for Pfizer-BioNTech’s bivalent booster in people 12 and older and Moderna’s version in adults 18 and older. Eligible recipients may receive an updated booster at least two months after completing a primary series or receiving a previous booster.

A booster designed for the variant now circulating

The reformulated vaccines contain mRNA encoding the ancestral spike protein and an additional component directed at the BA.4/BA.5 spike. FDA’s August 31 authorization allowed the updated products to replace the older formulations for booster use in the covered age groups. Pfizer and BioNTech said their 30-microgram bivalent dose contains 15 micrograms directed at the original strain and 15 micrograms directed at BA.4/BA.5.

The scientific rationale is straightforward: immunity from vaccination and prior infection declines over time, while Omicron subvariants have accumulated mutations that allow them to evade some existing antibodies. CDC’s September epidemiology review presented to the Advisory Committee on Immunization Practices described the changing variant landscape and the continued burden of hospitalization and death, particularly among older adults.

CDC’s antigenic review also summarized how the emerging variants differ immunologically from earlier strains. The updated formulation is intended to broaden the immune response rather than simply provide another dose of the original vaccine.

ACIP votes 13-1 for both updated boosters

At its September 1 meeting, the Advisory Committee on Immunization Practices voted 13-1 to recommend each updated vaccine for the authorized population. The committee’s presentation archive includes separate reviews of epidemiology, vaccine effectiveness, safety, manufacturer data and implementation questions.

The committee’s evidence-to-recommendations framework concluded that the anticipated benefits outweighed the risks for the proposed booster groups. The vote also withdrew prior recommendations for monovalent Pfizer boosters in people 12 and older and monovalent Moderna boosters in adults, making the bivalent products the preferred next dose for eligible recipients.

The recommendation was made with a different evidence package than the one supporting the original vaccines. Human clinical data were available from an earlier bivalent formulation targeting Omicron BA.1, while the BA.4/BA.5 versions relied in part on preclinical data, manufacturing information and the accumulated safety record of the mRNA platform. Pfizer presented its Omicron-modified vaccine data directly to ACIP. The committee also reviewed extensive safety information from the existing vaccine program in a separate safety presentation.

Implementation shifts from repeated original-strain doses

The practical effect is a significant simplification for most adults and adolescents seeking another COVID-19 dose this fall. Instead of receiving another monovalent booster, eligible people are directed to the updated formulation. CDC’s clinical-considerations guidance says the new booster can be given at least two months after the most recent primary-series or booster dose, although clinicians may consider longer intervals in some circumstances.

The rollout begins as health officials try to improve protection before colder weather increases indoor activity. The government is relying heavily on pharmacies, clinics and other existing vaccination sites rather than rebuilding the mass-vaccination infrastructure used early in the campaign. Manufacturers said shipments could begin immediately after authorization, allowing doses to reach pharmacies within days.

For patients, the most important distinction is that the updated shot is a booster, not a replacement for the primary series. People who have not completed an initial vaccination series continue to use the authorized primary-series products. The new formulation is intended for people who have already established baseline immunity through vaccination and are due for an additional dose.

A test of whether reformulation can keep pace

The strategy resembles the periodic updating of influenza vaccines, but COVID-19 presents a different challenge because variant evolution is rapid and manufacturing decisions must be made before complete human effectiveness data are available. Regulators are betting that the well-characterized mRNA platform can be modified without repeating the full development path used for the original vaccines.

The policy also places more responsibility on surveillance. If BA.4 and BA.5 recede and a substantially different lineage takes over, the composition may again need to change. For now, however, those subvariants account for the overwhelming majority of U.S. infections, making them the most relevant available target for the fall booster campaign.

The launch therefore marks more than another dose in a long vaccination schedule. It is the beginning of an adaptive vaccine strategy in which the antigenic target is expected to change as the virus changes. Whether that strategy materially reduces severe disease through the fall and winter will depend on both the biological performance of the updated vaccines and the willingness of eligible Americans to receive them.